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Abstract 
Background and aims: Transforming growth factor-beta 1 (TGF-β1) and vascular 
adhesion molecule 1 (VCAM-1) have been proposed as promising biomarkers for multiple 
diseases. TGF-β1 and VCAM-1 are reported to be associated with diabetic kidney disease 
(DKD) and end stage renal disease in patients with type 1 and type 2 diabetes mellitus 
(T1DM and T2DM). Material and methods: The aim of this study was to investigate the 
expression of circulating TGF-β1 and VCAM-1 and to assess their potential as a blood-
based biomarker for DKD in T1DM and T2DM patients. Results:. The study included 124 
participants: 66 patients with T1DM, 58 with T2DM and 20 healthy controls. The 
diabetic patients were classified according to the estimated glomerular filtration rate 
(eGFR). First group - eGFR ≥90ml/min/1.73 m² (n=39), second group eGFR 89-60 
ml/min/1.73m² (n=45), and third group eGFR 59-45 ml/min/1.73m
2 
(n=40). Enzyme-
linked immunosorbent assay for the quantitative detection of was used to evaluate blood 
TGF- β1 and VCAM-1 expression. It was found that there were higher TGF- β1 and 
VCAM-1 in all diabetic patients compared with healthy controls (P<0.05). TGF- β1 and 
VCAM-1 were higher in group with eGFR ≥90ml/min/1.73 m² and gradually increased in 
the groups with eGFR89-60 ml/min/1.73m² and eGFR 59-45 ml/min/1.73m
2
. TGF- β1 and 
VCAM-1 were less in T1DM, than T2DM in all study groups. Regression analysis 
revealed reverse associations between TGF- β1, VCAM-1 and eGFR (P<0.05). TGF- β1 
and VCAM-1 correlated positively with albuminuria and negatively with renal function. 
Conclusion: In discriminating overall patients from healthy subjects, ROC analysis 
revealed areas under the curve (AUCs) of 1,0 for TGF- β1 for T1DM and T2DM, VCAM-
1 0,866 for T1DM, 0,923 for T2DM (P<0.001). The results suggested that blood-based 
TGF- β1 and VCAM-1 may serve as potential biomarkers for early detection of DKD. 
key words: VCAM-1; TGF- β1; endothelial dysfunction; diabetes mellitus; diabetic 
kidney disease progression 
Background and aim 
The prevalence of diabetes mellitus (DM) 
has tendency to increase worldwide. It is about 
425 million people with diabetes now and it may 
rise to 693 million by 2045 [1]. Epidemiological 
studies in Ukraine also indicate ongoing increase 
the number of patients with DM.  
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Chronic hyperglycemia is accompanied by 
lesion, dysfunction or insufficiency of various 
organs and systems. Eye retinal blood vessels 
and the kidney are primary affected by increased 
glucose level. Damage of kidney leads to 
diabetic kidney disease (DKD), which often 
leads to disability. The increasing number of 
patients with end stage renal disease (ESRD) 
cause significant social and economic losses 
around the world. 
Five-year survival rate of patients with 
T1DM and T2DM after DKD manifestation is 
about 77 and 70%, respectively [2]. These and 
other facts encourage researchers to seek new 
approaches to determining the early stages of 
DKD, for slowing the disease progression. 
Preclinical diagnostics of DKD may enable to 
prescribe therapy earlier and slow down the 
kidney disease progression. Thus, scientists are 
continuously looking for markers to detect DKD 
at the earliest stages, when changes in kidneys 
are reversible. 
Endothelial cells intensively regulate basal 
vascular tone tension and vascular reactivity 
under physiological and pathological conditions, 
by responding to mechanical forces and 
neurohumoral mediators with release of variety 
relaxing and contracting factors. Loss of the 
endothelium modulatory role may be a critical 
and initiation factor in the development of 
diabetic vascular disease. Now it is possible to 
select several variants of changes in the 
endothelium functional activity. Endothelial 
dysfunction as a reduction of factors that are 
constantly formed and excreted from endothelial 
cells like nitric oxide or prostacyclin. 
Stimulation of endothelium cause an increase in 
blood factors such as Willibrand, R-selectin and 
tissue plasminogen activator. Activation of 
endothelium include strong increase in blood 
concentrations of endothelin-1, intercellular 
adhesion molecule 1 (ICAM-1), vascular cell 
adhesion molecule-1 (VCAM-1), E-selectin, 
plasminogen activator inhibitor-1 (PAI-1). 
Notably, the concentrations of these factors are 
very low under heath conditions [3].  
Studies of the factors released during 
endothelial activation suggest their important 
role in the development of DKD [4,5]. Multiply 
studies showed that VCAM-1 is associated with 
DKD development in patients with T2DM [6,7]. 
Dong-Jin Kim and coauthors found that 
increased levels of transforming growth factor 
beta 1 (TGF-β1) were associated only with 
increased kidney fibrosis in mice with diabetes 
induced by ischemic reperfusion injury in kidney 
[8]. TGF-β1, a key profibrotic cytokine, is 
involved in renal fibrosis processes, dysfunction 
and renal tubular atrophy and reduces small 
vessels number causing chronic hypoxia. The 
studying of endothelial dysfunction factors is an 
actual now, therefore the diagnostic and 
prognostic value of these markers needs to be 
clarified and should be made statistically- 
mathematical substantiation for detection of 
DKD progression.  
To evaluate the significance of using 
transforming growth factor-beta 1 and vascular 
adhesion molecule-1 as prognostic markers of 
diabetic kidney disease progression in patients 
with diabetes mellitus type 1 and 2. 
Material and methods 
The study involved 124 patients with 
diabetes, 66 with T1DM and 58 with T2DM. 
Among the patients - 68 women and 56 men 
aged from 18 to 64 (33 ± 5.6). Duration of DM 
was 3.5-25 (12 ± 6.3) years. Patients were 
divided into three groups depending on the 
eGFR. Patients of first group had eGFR 
≥90ml/min/1.73 m²; of the second group - 89-60 
ml/min/1.73m², and third group - 59-45 
ml/min/1.73m
2
. Next patients were excluded 
from the study: patients with T1DM, T2DM and 
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eGFR ≤45 ml/min/1.73 m2, secondary diabetes, 
gestational diabetes, diabetic ketoacidosis, 
severe hypoglycemia, severe concomitant 
pathology. The control group consisted of 20 
healthy volunteers. The study was performed at 
endocrinology department of the "Clinic of the 
Medical Academy", Dnipro, 2016-2017. 
Creatinine levels were measured using the 
test kit «SpinLab» (Ukraine). eGFR was 
calculated by CKD-EPI (Chronic Kidney 
Disease Epidemiology Collaboration). The 
endothelial function was determined by 
measurements of concentration of TGF-1 and 
VCAM-1 using the «Bender Medsystems» 
(Austria) and «BCM Diagnostics» (Ukraine). 
Measurements were conducted in Diagnostic 
Center of «Pharmacy of Medical Academy», 
Dnipro. 
The study was conducted according to the 
ethical principles of the Helsinki Declaration 
with the permission of the Bioethical 
Commission of the SE "Dnipropetrovsk Medical 
Academy of the Ministry of Health of Ukraine". 
Data were analyzed using Microsoft Excel 
add-on program AtteStat, software 
STATISTICA 6.1, and MedCalc Version 18.2.1 
(https://www.medcalc.org/download.php). 
ROC (Recognitive Operating Characteristic) 
was used to assess the discrimination ability 
(diagnostic test value) of the TGF-1 and 
VCAM-1 as predictors of DKD progression. The 
result was represented by the area under the 
ROC curve (AUC) based on test sensitivity (Se) 
and specificity (Sp) and with a 95% confidence 
interval (95% CI). Calculations of the AUC and 
the difference between two AUCs were 
performed using DeLong et al. [9]. ROC-
analysis considered adequate if statistically 
significant differences in AUC value was more 
than 0.7. The values of the area under the ROC 
curve were interpreted as diagnostic accuracy: 
0.9-1.0 – excellent method operating 
characteristic; 0,8-0,9 - very good; 0,7-0,8 - 
good; 0.6-0.7 - average; 0.5-0.6 - unsatisfactory; 
the value less than 0.5 mean that the method is 
non-effective [10]. The threshold predictive 
values of the diagnostic tests were determined by 
the optimal cut-off point of the ROC curve 
calculated using the J-Youden index (the 
maximum vertical distance between the ROC 
curve and the diagonal referential line) by the 
ratio (J = Se + Sp-1) [11]. The critical level of 
statistical significance (p) was taken <5% 
(p<0,05). 
Results and Discussion 
Patients of all studied groups had 
significantly higher levels of TGF-β1 in the 
circulation (Fig. 1). This clearly demonstrate that 
diabetes on both types induce endothelial 
dysfunction. Shortly, patients of first group with 
T2DM had 1.14 fold higher level of TGF-β1. 
TGF-β1 levels were 3.85 and 4.68 fold increased 
in T1DM and T2DM patients of second eGFR 
group. Patients of third group with diabetes had 
8.0 and 8.2 fold higher levels of TGF-β1 
compared to control. Interestingly, the difference 
in TGF-β1 levels were also different in patients 
with T1DM and T2DM related to eGFR groups 
one and two (Fig. 1). TGF-1 was increased 
with decreasing of eGFR regardless of type of 
diabetes. The levels of TGF-1 were 57 and 
78% higher in patients of second and third 
groups in comparison with those of first group.  
It was shown that differences between levels 
of TGF-1 (p1-2 = 0.001; p1-3 <0.001) and 
VCAM-1 (p1-2 = 0.001; p1-3 <0.001) in the 
study groups were the statistically significant.  
It was determined that levels of TGF-1 and 
VCAM-1 have by reverse strong correlation with 
eGFR (ρ = -0.56, p <0.001) and (ρ = -0.51, 
p<0.001) respectively. The less eGFR, the higher 
rates of TGF-1 and VCAM-1, which indicates 
the progression of endothelial dysfunction.  
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Fig. 1. The TGF- β1 levels in healthy and individuals T1DM and T2DM ranged into three types of eGFR (1, 2 and 3). 
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Fig. 2. The VCAM-1 levels in study groups. 
ROC analysis was conducted to evaluate the 
possibility of using endothelial function proteins 
TGF-β1 and VCAM-1 as prognostic markers of 
DKD progression. For such an analysis the 
patients were separated into two subgroups 
based on eGFR. Subgroup A included 39 
patients without nephropathy and eGFR 90 
ml/min/1.73 m
2
. Patients of subgroup B (40 
patients) had clinically proven DKD and eGFR 
59-45 90 ml/min/1.73 m
2
. The analysis was 
conducted among all patients in general and 
taking into account the DM type. Since 
albuminuria (AU) is a one of the main diagnostic 
criteria for DKD [12] the diagnostic values of 
TGF-1 and VCAM-1 were compared with the 
value of AU.  
Test sensitivity it’s a probability of positive 
test result in the presence of the disease, and test 
specificity it’s a probability of negative test 
result in the absence of the disease. We 
compared the predictive power of the studied 
tests on DKD progression using ROC-analysis. 
The area under the ROC curve of all investigated 
laboratory tests is more than 0.7 (p <0.001), so 
they all have a predictive value for detection of 
DKD progression. 
We have done a pairwise comparison of the 
tests operating characteristics and found that 
TGF-b1 had a statistically significant difference 
(Fig. 3) with AU (difference between AUCs 
0.204 at 95% CI 0.067-0.340; p = 0.004) and 
withVCAM-1 (difference between AUCs 0.134 
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at 95% CI 0.002 - 0.268; p = 0.049) in patients 
with T1DM. While there was no statistically 
significant difference between the ROC curves 
for predicting DKD progression of AU and 
VCAM-1 (p> 0.05). 
 
Fig. 3. Prognostic ROC curves of diabetic kidney disease 
based on the levels of albuminuria, VCAM-1 and TGF-b1 
in patients with diabetes mellitus type1. 
 
Fig. 4. Prognostic ROC curves of diabetic kidney disease 
based on the levels of albuminuria, VCAM-1 and TGF-b1 
in patients with diabetes mellitus type2. 
The difference between the areas under ROC 
curves of AU and VCAM-1 was also not 
statistically significant (p> 0.05) in patients with 
T2DM. We also didn’t find statistically 
significant differences between ROC curves of 
VCAM-1 and TGF-1 in patients with T2DM 
(difference between AUCs was 0.077 at 95% CI 
-0.029-0.184; p = 0.156). The difference 
between areas under ROC curves of AU and 
TGF-b1 was 0.225 (95% CI 0.065 - 0.386, p = 
0.006). 
 
Fig. 5. Prognostic ROC curves of diabetic kidney disease 
based on the levels of albuminuria, VCAM-1 and TGF-b1 
in patients with diabetes mellitus types1 and 2. 
Thus, selected endothelial function markers - 
VCAM-1 and TGF-1 can be used for predicting 
DKD progression in patients with diabetes both 
types. It is important to emphasize that the 
diagnostic capabilities of VCAM-1 and TGF-1 
in predicting DKD progression exceed the 
diagnostic capabilities of AU. 
The optimal cut-off point used as the critical 
level for deciding DKD is progressing. 
According to our research for the AU the critical 
value corresponds to well-known data and is> 
35.2 mg / l. For the VCAM-1 in patients with 
T1DM the cut-off point level is higher than 
901.92 pg / ml; in patients with T2DM - more 
than 964.44 pg / ml, for both types of diabetes - 
more than 922.5 pg / ml. For the TGF-1 the 
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optimal cut-off point level for deciding that 
DKD is going to progress in patients with 
diabetes 1 and 2 types is more than 
52281.6 ng/ml. 
In our study, it was determined that 
albuminuria has “good” operating characteristics 
concerning DKD progression: Se = 57,50; Sd = 
97.44; AUC = 0.785; p <0,001 for type1 and 2 
DM. However, the evaluation of albuminuria in 
diabetes has a high specificity, but low 
sensitivity of the prognosis of DKD progression. 
We traced this pattern for both types of diabetes. 
VCAM-1 has “excellent” operating 
characteristics for predicting DKD progression 
in patients with T2DM (Se = 100,0; SP = 88,89; 
AUC = 0,923; p <0.001) and “very good” in 
patients with T1DM (Se = 86,36; Sp = 90.48; 
AUC = 0.866; p <0.001). 
The best operating characteristics (the 
highest sensitivity and specificity, AUC) has 
TGF-1, its predictive ability concerning DKD 
progression can be assessed as “exellent” for 
both types of diabetes (Se = 100.0; Sr = 100.0; 
AUC = 1.000; p < 0.001). 
Conclusions 
In our study it has been determined that 
endothelial function markers TGF-β1 and 
VCAM-1 can be used to predicting diabetic 
kidney disease progression in patients with type 
1 and type 2 diabetes. 
Diagnostic capabilities VCAM-1 (the 
difference between AUCs of 0.134 at 95% CI 
0.002 - 0.268; p = 0.049) and TGF-1 
(difference between AUCs 0.225 at 95% CI 
0.066 - 0.386; p = 0.006) for predicting DKD 
progression significantly exceed the diagnostic 
capabilities of albuminuria, which determines 
VCAM-1 and TGF-1 as early markers. 
According to the results of the pairwise 
comparison of predictive capabilities between 
TGF-1 and VCAM-1, it was determined that 
the best operating characteristics for the 
prognosis of DKD progression has TGF-1, in 
patients with both types of diabetes. That is why 
TGF-1 can be recommended for using as an 
early diagnostic marker of diabetic kidney 
disease progression. 
We defined the optimal cut-off point levels 
for predicting DKD progression: for the 
VCAM-1 in patients with T1DM – more than 
901.92 pg/ml, in patients with T2DM – more 
than 964.44 pg/ml, for both types of diabetes – 
more than 922.5 pg/ml. For the TGF-b1 the 
optimal cut-off point level for predicting DKD 
progression is more than 52281.6 ng/ml in 
patients with T1DM and T2DM separately and 
in general. 
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